177 related articles for article (PubMed ID: 21356308)
1. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
[TBL] [Abstract][Full Text] [Related]
2. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
3. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
4. A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein.
Shimizu T; Miyakawa Y; Iwata S; Kuribara A; Tiganis T; Morimoto C; Ikeda Y; Kizaki M
Exp Hematol; 2004 Nov; 32(11):1057-63. PubMed ID: 15539083
[TBL] [Abstract][Full Text] [Related]
5. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
6. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
8. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
[TBL] [Abstract][Full Text] [Related]
9. Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line.
Tarumoto T; Nagai T; Ohmine K; Miyoshi T; Nakamura M; Kondo T; Mitsugi K; Nakano S; Muroi K; Komatsu N; Ozawa K
Exp Hematol; 2004 Apr; 32(4):375-81. PubMed ID: 15050748
[TBL] [Abstract][Full Text] [Related]
10. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
[TBL] [Abstract][Full Text] [Related]
11. Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells.
Bernardo PS; Reis FR; Maia RC
Leuk Res; 2012 Dec; 36(12):1510-6. PubMed ID: 22975581
[TBL] [Abstract][Full Text] [Related]
12. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.
Nambu T; Araki N; Nakagawa A; Kuniyasu A; Kawaguchi T; Hamada A; Saito H
Cancer Sci; 2010 Jan; 101(1):137-42. PubMed ID: 19843070
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.
Ito T; Tanaka H; Kimura A
Eur J Haematol; 2007 May; 78(5):417-31. PubMed ID: 17432977
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
16. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Lothstein L; Savranskaya L; Sweatman TW
Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.
Illmer T; Schaich M; Platzbecker U; Freiberg-Richter J; Oelschlägel U; von Bonin M; Pursche S; Bergemann T; Ehninger G; Schleyer E
Leukemia; 2004 Mar; 18(3):401-8. PubMed ID: 14724652
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
20. Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells.
Mlejnek P; Dolezel P; Faber E; Kosztyu P
Ann Hematol; 2011 Jul; 90(7):837-42. PubMed ID: 21225261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]